OTC:ESALF

Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)

Retrieved on: 
Thursday, April 18, 2024
Alzheimer's disease, University, Genetics, Treatment, Award, Research, Postgraduate education, MEXT, Ministry, Disease, Faculty, Biomarker, Clinical trial, Drug discovery, Culture

TOKYO, Apr 18, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Based on its Pathological Mechanisms" has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology.

Key Points: 
  • TOKYO, Apr 18, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Based on its Pathological Mechanisms" has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology.
  • The Ministry of Education, Culture, Sports, Science and Technology (MEXT) grants this award to individuals who have made remarkable achievements regarding research, development, and knowledge enhancement in the field of science and technology, with the aim of encouraging those who engage in the field and raising the standard of Japanese science and technology.
  • This award is presented to individuals who have completed original research and development projects with high potential to contribute to the advancement of science and technology in Japan.
  • Prof. Takeshi Iwatsubo (Graduate School of Medicine and Faculty of Medicine, the University of Tokyo) Teiji Kimura (Global Alzheimer's Disease Head, Global Collaboration Network Lead, Senior Group Officer, Eisai Co., Ltd.)

Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan

Retrieved on: 
Wednesday, April 17, 2024
Seizure, Marketing, NHI, Eisai, Patient, AMPA, National health insurance, Neurology, AED, Epilepsy, Pharmaceutical industry

TOKYO, Apr 17, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan.

Key Points: 
  • TOKYO, Apr 17, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan.
  • The injection formulation of Fycompa received manufacturing and marketing approval on January 18, 2024 and was included in the Japan's National Health Insurance (NHI) Drug Price List today.
  • Two oral formulations of Fycompa are available in Japan: a tablet and a fine granule formulation.
  • Since Fycompa is the only AMPA receptor antagonist-based AED, Eisai developed this injection formulation to meet the needs of patients who are unable to use oral administration, and leading to the launch today.

French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics

Retrieved on: 
Wednesday, April 3, 2024
Parkinson's disease, Ecosystem, Psychiatry, Health, Eisai, Loxapine, Dependent territory, CNX, Patient, Global Health, Neurology, Marketing, Therapy, Anxiety, Pharmaceutical industry

TOKYO, Apr 3, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S.

Key Points: 
  • TOKYO, Apr 3, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S.
  • entered into an agreement to transfer the rights in France, the French Overseas Territories and Algeria (the "Territory") for the antipsychotic, "Loxapac" (generic name: loxapine) and the Parkinson's disease treatment "Parkinane LP" (generic name: trihexyphenidyl hydrochloride) to CNX Therapeutics Limited.
  • Eisai anticipates no changes to its consolidated financial forecast for the period ending March 31, 2024.
  • acquired the rights to both treatments in the Territory in July 2002 and has been marketing them since.

Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

Retrieved on: 
Monday, April 1, 2024
Biogen, FDA, Brain, Administration, MCI, State, Fast Track, Dementia, Cell, Clarity, Eisai, Biologics license application, European, Alzheimer's disease, OLE, Patient, BLA, Neuron, Plaque, Lecanemab

LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment or mild dementia stage of disease (collectively referred to as early AD).

Key Points: 
  • LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment or mild dementia stage of disease (collectively referred to as early AD).
  • Eisai had aimed to submit a Biologics License Application (BLA) for weekly maintenance therapy using subcutaneous (SC) administration in March 2024.
  • However, Eisai was recently informed by the FDA that a Fast Track designation specific for the SC formulation is needed to receive rolling review.
  • Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical

Retrieved on: 
Friday, March 29, 2024
Health, Marketing, Vertigo, Eisai, Ecosystem, Patient, Anxiety, Global Health, Neurology, Pharmaceutical industry

TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) and muscle relaxant Myonal (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd.

Key Points: 
  • TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) and muscle relaxant Myonal (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd.
    Merislon and Myonal have been widely used by patients in Japan for a long time since their launch in 1969 and 1983, respectively.
  • Eisai has determined that divesting rights for these products to Kaken, which has strengths in the products' disease areas, is the most optimal choice to ensure them to continue contributing to a greater number of patients.
  • Eisai anticipates no changes to its consolidated financial forecast for the period ending March 31, 2024.
  • Driven by our hhc concept, Eisai strives to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas: Neurology, Oncology and Global Health.

Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture

Retrieved on: 
Friday, March 29, 2024
Eisai

TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that "NouKNOW", Eisai's self-check tool for brain health, was certified as a "ME-BYO BRAND" by Kanagawa prefecture.

Key Points: 

TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that "NouKNOW", Eisai's self-check tool for brain health, was certified as a "ME-BYO BRAND" by Kanagawa prefecture.

Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024

Retrieved on: 
Friday, March 29, 2024
Cyclopropane, PSJ, Safety, Sleep, Royal Pharmaceutical Society, Lemborexant, Research, Insomnia, Protein, Development, Alzheimer's disease, Disease, Patient, Executive director, AMPA, Neurology, Medicine, Drug discovery, Drug development, Eribulin, CEG, Pharmaceutical industry

TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that drug discovery research conducted on lemborexant (brand name: Dayvigo), the dual orexin receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2024 by the PSJ.

Key Points: 
  • TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that drug discovery research conducted on lemborexant (brand name: Dayvigo), the dual orexin receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2024 by the PSJ.
  • The PSJ Award for Drug Research and Development is one of a series of awards presented by the PSJ and is dedicated to researchers who have conducted outstanding research work that has contributed to medicine through the innovative development of a pharmaceutical drug or applicable technology related to the pharmaceutical sciences.
  • Award recipients are evaluated by the PSJ based on the ingenuity of the research itself as well as the effectiveness and safety of the related pharmaceutical product(s) or the innovativeness of the related medical treatment or treatment technology.
  • Lemborexant is currently approved for the indication of insomnia in over 15 countries, including Japan, the U.S., Canada, Australia, and countries in Asia.

Lifenet and Eisai Co-Develop Dementia Insurance "be"

Retrieved on: 
Thursday, March 21, 2024
Brain, MCI, Aftercare, LINE, Learning, Dementia, Air Methods, Forgetting, Annual report, Insurance, Transport, Attention, Disease, Exercise, QR, Nursing, Prevalence, Diagnosis, Memory, Ageing, Drug discovery, Cabinet Office, Residential care

TOKYO, Mar 21, 2024 - (JCN Newswire) - LIFENET INSURANCE COMPANY and Eisai Co., Ltd. announced today that they have co-developed Dementia Insurance "be", a dementia insurance that supports early detection and treatment of dementia and mild cognitive impairment (hereafter, "MCI") as one of the initiatives under the capital and business alliance agreement concluded in August 2022 for collaboration in dementia and other areas.

Key Points: 
  • TOKYO, Mar 21, 2024 - (JCN Newswire) - LIFENET INSURANCE COMPANY and Eisai Co., Ltd. announced today that they have co-developed Dementia Insurance "be", a dementia insurance that supports early detection and treatment of dementia and mild cognitive impairment (hereafter, "MCI") as one of the initiatives under the capital and business alliance agreement concluded in August 2022 for collaboration in dementia and other areas.
  • MCI is the stage just before dementia diagnosis, where cognitive function is somewhere between the healthy and dementia states.
  • This dementia insurance product is offered by Lifenet.
  • Dementia Insurance "be" supports the early detection and treatment of dementia, increasing treatment options by providing generous coverage from the MCI stage.